Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 10/20 | 0.66 |
| ▸ | HTR1A | P08908 | 3/20 | 0.66 |
| ▸ | HTR6 | P50406 | 3/20 | 0.66 |
| ▸ | HTR2A | P28223 | 2/20 | 0.66 |
| ▸ | HTR5A | P47898 | 2/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.49 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.45 |
| ▸ | HTR3B | O95264 | 2/20 | 0.45 |
| ▸ | HTR3A | P46098 | 2/20 | 0.45 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.45 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | NCF1 | P14598 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30009739 | 1.00 | HTR7 (0.66) | HTR7HTR1AHTR6HTR2AHTR5A | |
| SCHEMBL2548096 | 0.87 | HTR7 (0.51) | HTR7HTR1AHTR6HTR2AHTR5A | |
| SCHEMBL30022433 | 0.80 | HTR7 (1.00) | HTR7HTR1AHTR6HTR2AHTR5A | |
| SCHEMBL3759275 | 0.80 | HTR7 (1.00) | HTR7HTR1AHTR6HTR2AHTR5A | |
| Hydrochloric Acid SCHEMBL1673713 | 0.78 | HTR7 (0.96) | HTR7HTR1AHTR6HTR2AHTR5A | |
| SCHEMBL4911490 | 0.75 | CYP1A2 (0.52) | HTR7HTR1AHTR6HTR2AHTR5A | |
| SCHEMBL941809 | 0.74 | HTR7 (1.00) | HTR7HTR1AHTR6HTR2AHTR5A | |
| SCHEMBL6630428 | 0.74 | HDAC2 (0.42) | HTR7CYP1A2LMNACYP3A4MAPT | |
| SCHEMBL7830202 | 0.73 | HTR7 (0.58) | HTR7HTR1AHTR6HTR2AHTR5A | |
| SCHEMBL15834279 | 0.73 | ADRB1 (0.75) | HTR7HTR1AHTR6HTR2AHTR5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12227485-B2 | Compounds useful for the treatment of infection with Mannheimia haemolytica or Histophilus somni | INTERVET INC. (US) | 2025-02-18 | — | — | US | disclosed |
| US-12157717-B2 | Compounds for the treatment of bovine or swine respiratory disease | INTERVET INC. (US) | 2024-12-03 | — | — | US | disclosed |
| US-12077488-B2 | Compounds useful for treating a Mannheimia haemolytica or Histophilus somni infection | INTERVET INC. (US) | 2024-09-03 | — | — | US | disclosed |
| CN-110072844-B | Compounds for the treatment of infection by Mannheimia haemolytica or histophilus somni | 英特维特国际股份有限公司 | 2023-06-02 | — | — | CN | disclosed |
| US-20230000813-A1 | COMPOUND FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE | INTERVET INC. (US) | 2023-01-05 | — | — | US | disclosed |
| CN-110300578-B | Compounds for the treatment of respiratory diseases in cattle or pigs | 英特维特国际股份有限公司 | 2022-12-13 | — | — | CN | disclosed |
| US-11406617-B2 | Compounds for the treatment of bovine or swine respiratory disease | INTERVET INC. (US) | 2022-08-09 | — | — | US | disclosed |
| US-20220041547-A1 | Compounds Useful for Treating a Mannheimia Haemolytica or Histophilus Somni Infection | INTERVET INC. (US) | 2022-02-10 | — | — | US | disclosed |
| US-20210347730-A1 | COMPOUNDS FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE | INTERVET INC. (US) | 2021-11-11 | — | — | US | disclosed |
| US-20210292284-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF INFECTION WITH MANNHEIMIA HAEMOLYTICA OR HISTOPHILUS SOMNI | INTERVET INC. (US) | 2021-09-23 | — | — | US | disclosed |
| WO-2004087153-A2 | USE OF ORGANIC COMPOUNDS FOR IMMUNOPOTENTIATION | CHIRON CORPORATION (US) | 2004-10-14 | — | — | WO | disclosed |
| US-20040176385-A1 | Small molecule PI 3-kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2004-09-09 | — | — | US | disclosed |
| WO-2004062601-A2 | ANTIBACTERIAL AGENTS | CHIRON CORPORATION (US) | 2004-07-29 | — | — | WO | disclosed |
| WO-2004060308-A2 | THIOSEMICARBAZONES AS ANTI-VIRALS AND IMMUNOPOTENTIATORS | CHIRON CORPORATION (US) | 2004-07-22 | — | — | WO | disclosed |
| US-20040122237-A1 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | NOVARTIS AG (CH) | 2004-06-24 | — | — | US | disclosed |
| WO-2004048365-A1 | 2,4,6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | CHIRON CORPORATION (US) | 2004-06-10 | — | — | WO | disclosed |
| US-20040087626-A1 | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase | NOVARTIS AG (CH) | 2004-05-06 | — | — | US | disclosed |
| US-20040077707-A1 | Pyrrole based inhibitors of glycogen synthase kinase 3 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2004-04-22 | — | — | US | disclosed |
| WO-2004018455-A1 | PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2004-03-04 | — | — | WO | disclosed |
| WO-2003082272-A1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS RAF KINASE INHIBITORS | CHIRON CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122237-A1 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | BRAF, RAF1, ARAF | HTR7 3933/4885HTR1A 4695/4885HTR6 4601/4885 |
| US-12077488-B2 | Compounds useful for treating a Mannheimia haemolytica or Histophilus somni infection | SORD, HEXD, SNRPD1 | HTR7 1582/4885HTR1A 2162/4885HTR6 2077/4885 |
| US-20040087626-A1 | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase | BRAF, RAF1, ARAF | HTR7 3757/4885HTR1A 4716/4885HTR6 4541/4885 |
| US-20220041547-A1 | Compounds Useful for Treating a Mannheimia Haemolytica or Histophilus Somni Infection | SORD, HEXD, SNRPD1 | HTR7 1582/4885HTR1A 2162/4885HTR6 2077/4885 |
| US-20210347730-A1 | COMPOUNDS FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE | PIGS, BTD, PPARD | HTR7 2249/4885HTR1A 2086/4885HTR6 1985/4885 |
| US-20210292284-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF INFECTION WITH MANNHEIMIA HAEMOLYTICA OR HISTOPHILUS SOMNI | SORD, HEXD, SDHA | HTR7 1692/4885HTR1A 2268/4885HTR6 2010/4885 |
| US-12227485-B2 | Compounds useful for the treatment of infection with Mannheimia haemolytica or Histophilus somni | SORD, HEXD, SNRPD1 | HTR7 1610/4885HTR1A 2083/4885HTR6 2016/4885 |
| US-20040176385-A1 | Small molecule PI 3-kinase inhibitors and methods of their use | PI4KB, PI4KA, PDPK1 | HTR7 2809/4885HTR1A 3025/4885HTR6 2451/4885 |
| US-11406617-B2 | Compounds for the treatment of bovine or swine respiratory disease | PIGS, BTD, PPARD | HTR7 2467/4885HTR1A 2833/4885HTR6 2066/4885 |
| US-12157717-B2 | Compounds for the treatment of bovine or swine respiratory disease | PIGS, BTD, PPARD | HTR7 2249/4885HTR1A 2086/4885HTR6 1985/4885 |
| US-20040077707-A1 | Pyrrole based inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, PYGB | HTR7 3960/4885HTR1A 3938/4885HTR6 3577/4885 |
| US-20230000813-A1 | COMPOUND FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE | PIGS, BTD, BRD1 | HTR7 2788/4885HTR1A 3165/4885HTR6 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.